Disc Medicine, Inc. (IRON)

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASH Annual Meeting in Orlando, FL. The data demonstrated that treatment with DISC-0974 resulted in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types.

Disc Medicine, Inc. ( IRON ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants John Quisel - CEO, President & Director Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Hello, everyone. Welcome to Jefferies London Healthcare Conference 2025.

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Disc Medicine, Inc. ( IRON ) Stifel 2025 Healthcare Conference November 13, 2025 8:40 AM EST Company Participants Jonathan Yu - Chief Opearating Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division So we're going to go ahead and get started. I'm Steve Willey, one of the senior biotech analysts here at Stifel.

Shares of Ironveld Plc (LON: IRON - Get Free Report) rose 10% during trading on Friday. The company traded as high as GBX 0.06 and last traded at GBX 0.06. Approximately 259,699,203 shares changed hands during mid-day trading, an increase of 262% from the average daily volume of 71,806,461 shares. The stock had previously closed

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at three upcoming investor conferences:

Shares of Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) have received an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating

Does Disc Medicine, Inc. (IRON) have what it takes to be a top stock pick for momentum investors? Let's find out.

The consensus price target hints at a 26.3% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of the upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Disc is selling 2,619,049 shares of common stock and pre-funded warrants to purchase 59,523 shares of common stock and AI DMI LLC (the Selling Stockholder) is selling 297,619 shares of common stock in the offering. The shares of common stock are being sold at an offering price of $84.00 per share, and the pre-funded warrants are being sold at an offering price of $83.9999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Disc from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. The aggregate gross proceeds to the Selling Stockholder from this offering are expected to be approximately $25 million, before deducting underwriting discounts and commissions. In addition, the Selling Stockholder has granted the underwriters a 30-day option to purchase up to an additional 446,428 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 22, 2025, subject to the satisfaction of customary closing conditions.

Disc Medicine receives a "Strong Buy" rating due to significant progress with bitopertin for EPP and XLP treatment. IRON submitted an NDA for bitopertin under Accelerated Approval, supported by positive BEACON and AURORA phase 2 study results showing reduced PPIX and improved QoL. The company earned a rare Commissioner's National Priority Review Voucher (CNPV), potentially expediting FDA review to as little as 1-2 months.

WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten offering of $220.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, of which $200.0 million of shares are to be offered by Disc and $20.0 million of shares are to be offered by AI DMI LLC (the Selling Stockholder). In addition, the Selling Stockholder intends to grant the underwriters a 30-day option to purchase up to an additional $33.0 million of shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline and operational progress and strategic priorities for the rest of 2025 and 2026.

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will present clinical data as a poster presentation at the upcoming 2025 American Society of Nephrology (ASN) Kidney Week, which will be held in Houston, TX on November 6-9, 2025.

WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). Disc submitted the NDA under the FDA's accelerated approval pathway using reduction of protoporphyrin IX (PPIX) as a surrogate endpoint and requested a Priority Review based on bitopertin's potential to address the significant unmet need for EPP patients. Bitopertin has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA.